scholarly journals Prognostic and Clinicopathological Value of Cyclin E Expression in Breast Cancer: A Meta-Analysis

2021 ◽  
Author(s):  
Yufei Wang ◽  
Qijuan Yang ◽  
Deshou Ma ◽  
Zhijun Ma ◽  
Xiaowu Wang
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Meta Analysis ◽  
Cyclin E ◽  
Cochrane Collaboration ◽  
Clinicopathological Characteristics ◽  
Positive Lymph Node ◽  
Cancer Prognosis ◽  
Breast Cancer Patients ◽  
Cancer Specific Survival

Abstract Background: Multiple studies have analyzed the correlation between Cyclin E and breast cancer prognosis, but the results are controversial. In this study, a meta-analysis was used to summarize the published reports, clarify the predictive value of Cyclin E in breast cancer, and the relationship with clinicopathological characteristics.Methods: A systematic search was retrieved in PubMed, Embase, Web of Science, Cochrane Collaboration Library on the comprehensive search strategy up to 24 August 2020. recurrence-free survival (RFS), overall survival (OS), and breast cancer-specific survival (BCSS) was estimated using pooled hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (95% CIs) by univariate and multivariate analysis.Results: Twenty-eight eligible studies met our inclusion criteria. The present meta-analysis indicates that high cyclin E expression is independently associated with poor OS, BCSS, and RFS in female breast cancer patients by univariate and multivariate analysis. Furthermore, higher histological grades, estrogen receptor (ER)-negativity, positive lymph node metastasis, younger patients, and premenopausal status were associated with Cyclin E overexpression. Conclusions: High expression of Cyclin E is associated with poor breast cancer outcomes and relevant to multiple clinical characteristics.

scholarly journals The Prognostic Significance of Phosphatase and Tensin Homolog Loss in Breast Cancer

2019 ◽  
Vol 7 (21) ◽  
pp. 3716-3720
Author(s):  
Indri Windarti ◽  
Wirsma Arif Harahap ◽  
Ricvan Dana Nindrea ◽  
Eti Yerizel ◽  
Primaria Dewi Rustamadji
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Random Effect ◽  
Prognostic Significance ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Breast Cancer Patients ◽  
Phosphatase And Tensin Homolog ◽  
Pten Loss ◽  
Tensin Homolog

AIM: This study aims to determine the prognostic significance of phosphatase and tensin homolog (PTEN) loss in breast cancer. METHODS: We conducted a meta-analysis study. Sample of this study were research articles that evaluated PTEN loss and prognosis in breast cancer patients. We searched for relevant studies published in PubMed and Proquest from January 2010 to July 2018. We reviewed studies that examined the association between immunohistochemical expression of PTEN and breast cancer prognosis using meta-analysis methods. Pooled risk ratios (RR) were calculated using fixed and random-effect models. Data were processed using Review Manager 5.3 (RevMan 5.3). RESULTS: There were 7 studies conducted a systematic review then continued to evaluate the association of PTEN loss and breast cancer prognosis by meta-analysis. There was a significant association of PTEN loss with poor prognosis of breast cancer (RR = 0.76 [95% CI 0.59-0.98 p <0.07), and there was not any significant publication bias for studies included. CONCLUSION: This study confirmed PTEN loss is an important independent factor for breast cancer prognosis.

scholarly journals Repercussions of melatonin on the risk of breast cancer: a systematic review and meta-analysis

2019 ◽  
Vol 65 (5) ◽  
pp. 699-705 ◽  
Author(s):  
Eduardo Carvalho de Arruda Veiga ◽  
Ricardo Simões ◽  
Vitor E Valenti ◽  
Jose Cipolla-Neto ◽  
Luiz Carlos Abreu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Cochrane Collaboration ◽  
Reproductive Period ◽  
Breast Cancer Patients ◽  
Language Data ◽  
Low Levels ◽  
The Cochrane Collaboration ◽  
And Control

SUMMARY Breast Cancer is common in women, but its etiology is not yet fully understood. Several factors may contribute to its genesis, such as genetics, lifestyle, and the environment. Melatonin may be involved in the process of breast cancer. Therefore, the aim of this study is to evaluate the influence of the levels of melatonin on breast cancer through a systematic review and meta-analysis. We performed a systematic review according to PRISMA recommendations. The primary databases MEDLINE, Embase, and Cochrane were consulted. There was no restriction on the year of publication and language. Data of systematic reviews from April 2017 to September to 2017 were analyzed. The meta-analysis was conducted using RevMan 5.3 software provided by the Cochrane Collaboration. From a total of 570 articles, 9 manuscripts were included in this review. They analy onzed women with breast cancer and control patients, of which 10% and 90% were in the reproductive period and after menopause, respectively. The lowest level of melatonin was found in approximately 55% of studies with breast cancer in post-menopause. The metanalyses of the studies demonstrated low levels of melatonin in breast cancer patients (n=963) compared with control patients (n= 1332), with a mean difference between the studies of −3.54 (CI −6.01, −1.06). Another difference found was in the comparison between smoking patients, with an average difference between 1.80 [0.97-2.63]. Our data suggest that low levels of melatonin might be a risk factor for breast cancer.

scholarly journals Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ziqi Jia ◽  
Jiaxin Li ◽  
Yuelun Zhang ◽  
Xin Wang ◽  
Jiahua Xing ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Contralateral Breast Cancer ◽  
Meta Analysis ◽  
Local Treatment ◽  
Local Therapy ◽  
Contralateral Breast ◽  
Systemic Review ◽  
Breast Cancer Patients ◽  
Cancer Specific Survival ◽  
Risk Reducing

Abstract Background Unilateral breast cancer (UBC) patients with germline pathogenic BRCA1/2 variants have a higher risk of developing contralateral breast cancer (CBC) and need contralateral risk-reducing local treatments, including contralateral risk-reducing mastectomy (CRRM) and prophylactic irradiation (CPI). The aim of our study was to systematically explore the efficacy of CRRM and CPI in reducing CBC risk and increasing survival. Methods A search was done, and eligible randomized trials and cohort studies should include and compare UBC patients with germline pathogenic BRCA1/2 variants who have and have not received contralateral risk-reducing local treatment. Random-effects meta-analysis was used in this study. Primary outcomes of the studies included overall survival (OS) and the incidence of contralateral breast cancer (CBC), and secondary outcomes included breast cancer-specific survival (BCSS). Results A total of five studies with 1769 UBC patients with germline pathogenic BRCA1/2 variants were enrolled in our meta-analysis. CRRM was correlated with a lower risk of CBC in UBC patients with germline pathogenic BRCA1/2 variants (summary RR = 0.07; 95%CI 0.03–0.13, I2 = 3%), a significantly increased OS (summary RR, 1.15; 95%CI 1.04–1.26, I2 = 26%) and a significantly increased BCSS (summary RR, 1.18; 95%CI 1.07–1.31, I2 = 64%) compared with surveillance. CPI also decreased the risk of CBC (RR 0.02; 95%CI 0.05–0.88) but did not significantly improve OS (RR 0.97; 95%CI 0.90–1.05) and BCSS (RR 0.97; 95%CI 0.90–1.05) compared with surveillance. Conclusions CRRM reduces CBC risk and increases OS and BCSS in UBC patients with germline pathogenic BRCA1/2 variants, and could be offered as a risk-reducing local treatment. For those who oppose CRRM, CPI could be offered for CBC-risk reduction, while its survival benefit is still uncertain.

Sign in / Sign up

Export Citation Format

Share Document